Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. today announced that the Journal of the American Medical Association (JAMA) has published positive results from a Phase 2a study of dupilumab in adult patients with moderate-to-severe chronic sinusitis with nasal polyposis who did not...
Genzyme, the specialty care global business unit of Sanofi,
today announced the recipients of the fifth annual Patient Advocacy
Leadership (PAL) awards. The global grant program supports projects by
non-profit organizations that serve patients living with lysosomal...
company, today announced positive new five-year investigational data
from the extension study of Lemtrada® (alemtuzumab) for
patients with relapsing remitting multiple sclerosis (RRMS). These
results will be presented on October 9, 2015 at the 31st...
company, announced today that magnetic resonance imaging (MRI) data from
the Phase III TEMSO study demonstrate that Aubagio®
(teriflunomide) significantly slowed brain volume loss (or atrophy) vs.
placebo over two years in people with relapsing...